

James Mittra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2483649/publications.pdf>

Version: 2024-02-01

23
papers

279
citations

1163117

8
h-index

996975

15
g-index

24
all docs

24
docs citations

24
times ranked

211
citing authors

#	ARTICLE	IF	CITATIONS
1	Political influences on biotechnology-based innovation for European agriculture: risk-assessment and risk management. <i>Technology Analysis and Strategic Management</i> , 2021, 33, 271-282.	3.5	5
2	Regulatory and market influences on innovation pathways for the development of new antimicrobial drugs. <i>Technology Analysis and Strategic Management</i> , 2021, 33, 283-295.	3.5	2
3	Understanding the emergence and evolution of new business models in the UK regenerative medicine sector. <i>Technology Analysis and Strategic Management</i> , 2021, 33, 320-333.	3.5	6
4	Unpacking the Concept of Bioeconomy: Problems of Definition, Measurement, and Value. <i>Science and Technology Studies</i> , 2020, 33, 2-21.	0.7	16
5	Re-Imagining Healthcare and Medical Research Systems in Post-Devolution Scotland. <i>Sociological Research Online</i> , 2019, 24, 55-72.	1.1	3
6	Regenerative medicine as a disruptive technology: implications for manufacturing & clinical adoption. <i>Cell & Gene Therapy Insights</i> , 2019, 5, 1287-1303.	0.1	3
7	Evolution of Business Models in Regenerative Medicine: Effects of a Disruptive Innovation on the Innovation Ecosystem. <i>Clinical Therapeutics</i> , 2018, 40, 1084-1094.	2.5	32
8	Conceptualising and practising multiple knowledge interactions in the life sciences. <i>Technological Forecasting and Social Change</i> , 2017, 116, 308-315.	11.6	5
9	Prospects for Harmonizing Regulatory Science Programs in Europe, Japan, and the United States to Advance Regenerative Medicine. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 724-733.	1.6	4
10	Organizational Transformations and the Value of Interdisciplinarity. , 2016, , 87-119.		0
11	The New Health Bioeconomy. , 2016, , .		17
12	Twenty-first century bioeconomy: Global challenges of biological knowledge for health and agriculture. <i>Science and Public Policy</i> , 2013, 40, 17-24.	2.4	32
13	Repairing the "Broken Middle"™ of the Health Innovation Pathway. <i>Science and Technology Studies</i> , 2013, 26, 103-123.	0.7	13
14	Analysing stratified medicine business models and value systems: innovation-regulation interactions. <i>New Biotechnology</i> , 2012, 29, 709-719.	4.4	21
15	From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries. <i>Trends in Biotechnology</i> , 2011, 29, 105-109.	9.3	15
16	Impact of the life sciences on organisation and management of R&D in large pharmaceutical firms. <i>International Journal of Biotechnology</i> , 2008, 10, 416.	1.2	12
17	Marginalising "eugenic anxiety"™ through a rhetoric of "liberal choice"™: a critique of the House of Commons Select Committee Report on reproductive technologies. <i>New Genetics and Society</i> , 2007, 26, 159-179.	1.2	2
18	Predictive Genetic Information and Access to Life Assurance: The Poverty of "Genetic Exceptionalism"™. <i>BioSocieties</i> , 2007, 2, 349-373.	1.3	10

#	ARTICLE	IF	CITATIONS
19	Evolution of the Life Science Industries. <i>Technology Analysis and Strategic Management</i> , 2007, 19, 251-255.	3.5	5
20	Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms. <i>Technology Analysis and Strategic Management</i> , 2007, 19, 279-301.	3.5	54
21	The Socio-Political Economy of Pharmaceutical Mergers: A Case Study of Sanofi and Aventis. <i>Technology Analysis and Strategic Management</i> , 2006, 18, 473-496.	3.5	7
22	“Genetic exceptionalism” and precautionary politics: regulating for uncertainty in Britain’s genetics and insurance policy process. <i>Science and Public Policy</i> , 2006, 33, 585-600.	2.4	9
23	Pharmaceutical industries: do they prefer treatment to cure?. <i>Biochemist</i> , 2005, 27, 32-34.	0.5	3